To confirm whether the increase in production of UBE2L6 led to the degradation of Mcl-1 in AML cells, after gilteritinib and HHT treatment, the mRNA expression was suppressed with the help of siRNA in MV4-11 and Molm13 cell lines (Figure 4(d)). The gene discussed is MCL1; the disease is acute myeloid leukemia.